Bio News
BioMarin has halted development of BMN 401, a rare disease drug it acquired for $270 million (approximately 380 billion won). BioMarin said the drug failed to meet one of its primary endpoints in a phase 3 trial. The company plans to strengthen its pipeline, supported by 20% second-quarter revenue growth.
Biobook Team
biobookmedia@biobook.co.krIonkura Reports 20.8-Month Median Survival in Phase 1 Trial for Metastatic Eye Cancer
Verastem’s VS-7375 Shows Response Rates of Up to 50% in Pancreatic Cancer; Phase 3 Trial to Begin This Year
Pfizer to Co-Develop Sec61 Inhibitors With Enodia in Deal Worth Up to $500 Million
Galderma to Acquire ZO Skin Health for $1.5 Billion, Expanding Dermatology Portfolio
Verdiva halts GLP-1 transition trial, citing ‘market changes’
Stryker to Invest $400 Million in CMR Surgical, Expand Robotic Surgery
